CG
CRSP icon

Caprock Group’s CRISPR Therapeutics CRSP Stock Holding History

Caprock Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$414K Buy
7,593
+2,943
+63% +$155K 0.01% 916
2026
Q1 		$221K Buy
4,650
+483
+12% +$25.5K 0.01% 1023
2025
Q4 		$219K Buy
4,167
+153
+4% +$9.16K ﹤0.01% 1089
2025
Q3 		$208K Buy
+4,014
New +$230K 0.01% 1053

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caprock Group's CRSP Position: Q2 2026 in Review

Caprock Group increased its CRISPR Therapeutics (CRSP) stake by 63% in Q2 2026, buying an estimated $155K and bringing the position to 7,593 shares worth $414K. The position accounts for 0.01% of the portfolio, ranked #916.

Caprock Group first reported a position in CRSP in Q3 2025 and has held it in 4 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Caprock Group held 7,593 shares of CRISPR Therapeutics worth $414K as of Q2 2026.
  • Caprock Group bought 2,943 CRISPR Therapeutics shares in Q2 2026, an estimated $155K.
  • CRISPR Therapeutics made up 0.01% of Caprock Group's portfolio in Q2 2026, its #916 holding.
  • Caprock Group first reported a position in CRISPR Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.